{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:12:54Z","timestamp":1790874774097,"version":"4.1.0"},"reference-count":22,"publisher":"American Psychiatric Association Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNP"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1176\/jnp.16.2.185","type":"journal-article","created":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T23:13:48Z","timestamp":1418858028000},"page":"185-191","source":"Crossref","is-referenced-by-count":64,"title":["Cognitive Dysfunction and Depression During Treatment With Interferon-Alpha and Chemotherapy"],"prefix":"10.1176","volume":"16","author":[{"given":"Randall S.","family":"Scheibel","sequence":"first","affiliation":[{"name":"Received June 7, 2002; revised October 22, 2002; accepted November 1, 2002. From the Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston; Departments of Neuro-Oncology and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston. Address correspondence to Dr. Meyers, Department of Neuro-Oncology (Box 431), U.T. M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, (E-mail)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Valentine","sequence":"additional","affiliation":[{"name":"Received June 7, 2002; revised October 22, 2002; accepted November 1, 2002. From the Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston; Departments of Neuro-Oncology and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston. Address correspondence to Dr. Meyers, Department of Neuro-Oncology (Box 431), U.T. M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, (E-mail)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Received June 7, 2002; revised October 22, 2002; accepted November 1, 2002. From the Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston; Departments of Neuro-Oncology and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston. Address correspondence to Dr. Meyers, Department of Neuro-Oncology (Box 431), U.T. M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, (E-mail)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A.","family":"Meyers","sequence":"additional","affiliation":[{"name":"Received June 7, 2002; revised October 22, 2002; accepted November 1, 2002. From the Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston; Departments of Neuro-Oncology and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston. Address correspondence to Dr. Meyers, Department of Neuro-Oncology (Box 431), U.T. M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, (E-mail)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R9047571","doi-asserted-by":"crossref","unstructured":"Meyers CA, Valentine AD: Neurological and psychiatric adverse effects of immunological therapy. CNS Drugs 1995; 3:56\u201368","DOI":"10.2165\/00023210-199503010-00006"},{"key":"R9047572","doi-asserted-by":"crossref","unstructured":"Capuron L, Gumnick JF, Musselman DL, et al: Neurobehavioral effects of interferon-\u03b1 in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26:643\u2013652","DOI":"10.1016\/S0893-133X(01)00407-9"},{"key":"R9047573","doi-asserted-by":"crossref","unstructured":"Pavol MA, Meyers CA, Rexer JL, et al: Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 1995; 45:947\u2013950","DOI":"10.1212\/WNL.45.5.947"},{"key":"R9047574","doi-asserted-by":"crossref","unstructured":"Mapou RL, Law WA, Wagner K, et al: Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals. J Neuropsychiatry Clin Neurosci 1996; 8:74\u201381","DOI":"10.1176\/jnp.8.1.74"},{"key":"R9047575","doi-asserted-by":"crossref","unstructured":"Merimsky O, Chaitchik S: Neurotoxicity of interferon-\u03b1. Anticancer Drugs 1992; 3:567\u2013570","DOI":"10.1097\/00001813-199212000-00002"},{"key":"R9047577","doi-asserted-by":"crossref","unstructured":"Capuron L, Ravaud A: Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state (letter). N Engl J Med 1999; 340:1370","DOI":"10.1056\/NEJM199904293401716"},{"key":"R9047578","doi-asserted-by":"crossref","unstructured":"Scalori A, Apale P, Roffi L: Psychological screening before interferon therapy (letter). Hepatology 2001; 33:480","DOI":"10.1053\/jhep.2001.21593"},{"key":"R9047579","doi-asserted-by":"crossref","unstructured":"Tarbuck AF, Paykel ES: Effects of major depression on the cognitive function of younger and older patients. Psychol Med 1995; 25:285\u2013296","DOI":"10.1017\/S0033291700036187"},{"key":"R90475710","doi-asserted-by":"crossref","unstructured":"Meyers CA, Scheibel RS, Forman AD: Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41:672\u2013676","DOI":"10.1212\/WNL.41.5.672"},{"key":"R90475712","doi-asserted-by":"crossref","unstructured":"Hannay HJ, Levin HS: Selective reminding test: an examination of the equivalence of four forms. J Clin Exp Neuropsychol 1985; 7:251\u2013263","DOI":"10.1080\/01688638508401258"},{"key":"R90475715","doi-asserted-by":"crossref","unstructured":"Miller E: Verbal fluency as a function of a measure of verbal intelligence and in relation to different types of cerebral pathology. Br J Clin Psychol 1984; 23:53\u201357","DOI":"10.1111\/j.2044-8260.1984.tb00626.x"},{"key":"R90475717","doi-asserted-by":"crossref","unstructured":"Beck AT, Ward CH, Mendelson M, et al: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561\u2013571","DOI":"10.1001\/archpsyc.1961.01710120031004"},{"key":"R90475719","doi-asserted-by":"crossref","unstructured":"McCaffrey RJ, Ortega A, Orsillo SM, et al: Practice effects in repeated neuropsychological assessments. Clin Neuropsychol 1992; 6:32\u201342","DOI":"10.1080\/13854049208404115"},{"key":"R90475720","doi-asserted-by":"crossref","unstructured":"Baker WJ, Royer GL Jr, Weiss RB: Cytarabine and neurologic toxicity. J Clin Oncol 1991; 9:679\u2013693","DOI":"10.1200\/JCO.1991.9.4.679"},{"key":"R90475721","doi-asserted-by":"crossref","unstructured":"Barry M, Clarke S, Mulcahy F, Back D: Hydroxyurea-induced neurotoxicity in HIV disease (letter). AIDS 1999; 13:1592\u20131594","DOI":"10.1097\/00002030-199908200-00028"},{"key":"R90475722","doi-asserted-by":"crossref","unstructured":"Blalock JE, Smith EM: Human leukocyte interferon: structural and biological relatedness to adrenocorticotrophic hormone and endorphins. Proc Natl Acad Sci USA 1980; 77:5972\u20135974","DOI":"10.1073\/pnas.77.10.5972"},{"key":"R90475723","doi-asserted-by":"crossref","unstructured":"Birmanns B, Saphier D, Abramsky O: \u03b1-Interferon modifies cortical EEG activity: dose-dependence and antagonism by naloxone. J Neurol Sci 1990; 100:22\u201326","DOI":"10.1016\/0022-510X(90)90007-A"},{"key":"R90475724","doi-asserted-by":"crossref","unstructured":"Ho BT, Huo YY, Lu JG, et al: Opioid-dopaminergic mechanisms in the potentiation of d-amphetamine discrimination by interferon-alpha. Pharmacol Biochem Behav 1992; 42:57\u201360","DOI":"10.1016\/0091-3057(92)90446-M"},{"key":"R90475725","doi-asserted-by":"crossref","unstructured":"Squire LR: Two forms of human amnesia: an analysis of forgetting. J Neurosci 1981; 1:635\u2013640","DOI":"10.1523\/JNEUROSCI.01-06-00635.1981"},{"key":"R90475726","doi-asserted-by":"crossref","unstructured":"Fletcher PC, Henson RNA: Frontal lobes and human memory: insights from functional brain imaging. Brain 2001; 124:849\u2013881","DOI":"10.1093\/brain\/124.5.849"},{"key":"R90475727","doi-asserted-by":"crossref","unstructured":"Juengling FD, Ebert D, Gut O, et al: Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) 2000; 152:383\u2013389","DOI":"10.1007\/s002130000549"},{"key":"R90475728","doi-asserted-by":"crossref","unstructured":"Valentine AD, Meyers CA, Talpaz M: Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest 1995; 13:561\u2013566","DOI":"10.3109\/07357909509024923"}],"container-title":["The Journal of Neuropsychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/jnp.16.2.185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T23:48:23Z","timestamp":1722383303000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/jnp.16.2.185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["10.1176\/jnp.16.2.185"],"URL":"https:\/\/doi.org\/10.1176\/jnp.16.2.185","relation":{},"ISSN":["0895-0172","1545-7222"],"issn-type":[{"value":"0895-0172","type":"print"},{"value":"1545-7222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}